Evidence map›Paper›PMID 27858284›Full record

ArticleEndocrine2017

Role of cannabinoid receptor 1 in human adipose tissue for lipolysis regulation and insulin resistance.

Cherno O Sidibeh, Maria J Pereira, Joey Lau Börjesson, Prasad G Kamble, Stanko Skrtic, Petros Katsogiannos, Magnus Sundbom, Maria K Svensson, Jan W Eriksson

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Endocrine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
1.5field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 53 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Cherno O SidibehDepartment of Medical Sciences, Uppsala University, Uppsala, Sweden.
Maria J PereiraDepartment of Medical Sciences, Uppsala University, Uppsala, Sweden.
Joey Lau BörjessonDepartment of Medical Sciences, Uppsala University, Uppsala, Sweden.
Prasad G KambleDepartment of Medical Sciences, Uppsala University, Uppsala, Sweden.
Stanko SkrticAstraZeneca R&D, Mölndal, Sweden.
Petros KatsogiannosDepartment of Medical Sciences, Uppsala University, Uppsala, Sweden.
Magnus SundbomDepartment of Surgical Sciences, Uppsala University, Uppsala, Sweden.
Maria K SvenssonDepartment of Medical Sciences, Uppsala University, Uppsala, Sweden.
Jan W ErikssonDepartment of Medical Sciences, Uppsala University, Uppsala, Sweden. jan.eriksson@medsci.uu.se.
Uppsala University · SEUniversity of Gothenburg · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We recently showed that the peripheral cannabinoid receptor type 1 (CNR1) gene is upregulated by the synthetic glucocorticoid dexamethasone. CNR1 is highly expressed in the central nervous system and has been a drug target for the treatment of obesity. Here we explore the role of peripheral CNR1 in states of insulin resistance in human adipose tissue. Subcutaneous adipose tissue was obtained from well-controlled type 2 diabetes subjects and controls. Subcutaneous adipose tissue gene expression levels of CNR1 and endocannabinoid synthesizing and degrading enzymes were assessed. Furthermore, paired human subcutaneous adipose tissue and omental adipose tissue from non-diabetic volunteers undergoing kidney donation or bariatric surgery, was incubated with or without dexamethasone. Subcutaneous adipose tissue obtained from volunteers through needle biopsy was incubated with or without dexamethasone and in the presence or absence of the CNR1-specific antagonist AM281. CNR1 gene and protein expression, lipolysis and glucose uptake were evaluated. Subcutaneous adipose tissue CNR1 gene expression levels were 2-fold elevated in type 2 diabetes subjects compared with control subjects. Additionally, gene expression levels of CNR1 and endocannabinoid-regulating enzymes from both groups correlated with markers of insulin resistance. Dexamethasone increased CNR1 expression dose-dependently in subcutaneous adipose tissue and omental adipose tissue by up to 25-fold. Dexamethasone pre-treatment of subcutaneous adipose tissue increased lipolysis rate and reduced glucose uptake. Co-incubation with the CNR1 antagonist AM281 prevented the stimulatory effect on lipolysis, but had no effect on glucose uptake. CNR1 is upregulated in states of type 2 diabetes and insulin resistance. Furthermore, CNR1 is involved in glucocorticoid-regulated lipolysis. Peripheral CNR1 could be an interesting drug target in type 2 diabetes and dyslipidemia.

Indexed as

Adipose TissueAgedDexamethasoneDiabetes Mellitus, Type 2Dose-Response Relationship, DrugFemaleGlucocorticoidsGlucoseHumansInsulin ResistanceLipolysisMaleMiddle AgedPiperidinesPyrazolesReceptor, Cannabinoid, CB1AM 251CNR1 protein, humanDexamethasoneGlucocorticoidsGlucosePiperidinesPyrazolesReceptor, Cannabinoid, CB1Adipose tissueEndocannabinoid systemGlucocorticoidsInsulin resistanceType 2 diabetes

Identifiers

PMID27858284
PMCPMC5316391
OpenAlexW2555174026

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.